Tocagen Inc.   Report issue

For profit Phase 1 Phase 3
Founded: San Diego CA United States (2007)
Status: Defunct (2020)

Organization Overview

First Clinical Trial
2010
NCT01156584
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Tocagen Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 3)

Glioblastoma (Phase 3)

Glioma (Phase 1)

Lymphoma (Phase 1)

Oligodendroglioma (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 6